Risperidone Long-acting Intramuscular Injectable for Bipolarity
This study is completed in the United States, in Austria, in India, .... It is testing Risperidone Long-acting Intramuscular Injectable for Bipolarity.
BipolarityDrugFrom 18 Years to 65 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether the Safety and Efficacy of Injectable Risperidone may be useful for adults experiencing bipolarity.
What would participation involve?
Participants may receive the Safety and Efficacy of Injectable Risperidone, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Austria, in India, and in Malaysia.
Who is it mainly for?
This study appears to be mainly for adults with bipolarity.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateFebruary 2005
Recruitment status
Completed
Enrollment listed in the registry
559
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Austria, India, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT00132678
Official title
A Randomized, Double-blind, Placebo-controlled Study to Explore the Efficacy and Safety of Risperidone Long-acting Intramuscular Injectable in the Prevention of Mood Episodes in Bipolar 1 Disorder, With Open-label Extension
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
Austria · 1 site
Neunkirchen
Neunkirchen
Site status: Not listed — confirm with the team
India · 3 sites
Bangalore
Bangalore
Site status: Not listed — confirm with the team
Hyderabad
Hyderabad
Site status: Not listed — confirm with the team
Manipal
Manipal
Site status: Not listed — confirm with the team
Malaysia · 3 sites
Johor Bahru
Johor Bahru
Site status: Not listed — confirm with the team
Kota Bharu
Kota Bharu
Site status: Not listed — confirm with the team
Kuala Lumpur
Kuala Lumpur
Site status: Not listed — confirm with the team
Poland · 4 sites
Choroszcz
Choroszcz
Site status: Not listed — confirm with the team
Gdansk
Gdansk
Site status: Not listed — confirm with the team
Swiecie Poland
Swiecie Poland
Site status: Not listed — confirm with the team
Tuszyn
Tuszyn
Site status: Not listed — confirm with the team
Russia · 9 sites
Lipetsk
Lipetsk
Site status: Not listed — confirm with the team
Moscow
Moscow
Site status: Not listed — confirm with the team
Moscow Region
Moscow Region
Site status: Not listed — confirm with the team
Moscow Russia
Moscow Russia
Site status: Not listed — confirm with the team
Nizny Novgorod
Nizny Novgorod
Site status: Not listed — confirm with the team
Saint Petersburg
Saint Petersburg
Site status: Not listed — confirm with the team
Samara
Samara
Site status: Not listed — confirm with the team
Saratov
Saratov
Site status: Not listed — confirm with the team
St-Petresburg
St-Petresburg
Site status: Not listed — confirm with the team
Slovakia · 3 sites
Bratislava
Bratislava
Site status: Not listed — confirm with the team
Košice
Košice
Site status: Not listed — confirm with the team
Rimavská Sobota
Rimavská Sobota
Site status: Not listed — confirm with the team
Spain · 2 sites
Barcelona
Barcelona
Site status: Not listed — confirm with the team
Madrid
Madrid
Site status: Not listed — confirm with the team
Taiwan · 4 sites
Taichung
Taichung
Site status: Not listed — confirm with the team
Tainan
Tainan
Site status: Not listed — confirm with the team
Taipei
Taipei
Site status: Not listed — confirm with the team
Taoyuan
Taoyuan
Site status: Not listed — confirm with the team
Ukraine · 8 sites
Dnipro
Dnipro
Site status: Not listed — confirm with the team
Hlevakha
Hlevakha
Site status: Not listed — confirm with the team
Kharkiv
Kharkiv
Site status: Not listed — confirm with the team
Kiev
Kiev
Site status: Not listed — confirm with the team
Lviv
Lviv
Site status: Not listed — confirm with the team
Odesa
Odesa
Site status: Not listed — confirm with the team
Simferopol
Simferopol
Site status: Not listed — confirm with the team
Vinnitsa
Vinnitsa
Site status: Not listed — confirm with the team
United States · 14 sites
Little Rock
Little Rock, Arkansas
Site status: Not listed — confirm with the team
La Mesa
La Mesa, California
Site status: Not listed — confirm with the team
National City
National City, California
Site status: Not listed — confirm with the team
Washington D.C.
Washington D.C., District of Columbia
Site status: Not listed — confirm with the team
Bradenton
Bradenton, Florida
Site status: Not listed — confirm with the team
Hialeah
Hialeah, Florida
Site status: Not listed — confirm with the team
Lake Charles
Lake Charles, Louisiana
Site status: Not listed — confirm with the team
Towson
Towson, Maryland
Site status: Not listed — confirm with the team
Clementon
Clementon, New Jersey
Site status: Not listed — confirm with the team
Lyndhurst
Lyndhurst, Ohio
Site status: Not listed — confirm with the team
Oklahoma City
Oklahoma City, Oklahoma
Site status: Not listed — confirm with the team
Philadelphia
Philadelphia, Pennsylvania
Site status: Not listed — confirm with the team
DeSoto
DeSoto, Texas
Site status: Not listed — confirm with the team
Richmond
Richmond, Virginia
Site status: Not listed — confirm with the team
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT00132678. We help you review the study, but cannot decide medical eligibility.
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with bipolarity. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving Risperdal Consta, Placebo. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.
Who might this study be for?
This study may concern people with bipolarity; age range: From 18 Years to 65 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which appears to be a pharmaceutical company. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.